Hyderabad, July 20, (HS) Mylan, the global pharma company today announced the commercial launch of Remdesivir under the brand name DESREM in India to address the urgent needs amidst the Covid-19 pandemic.
The drug is approved for the treatment of suspected or laboratory confirmed incidences of Covid-19 in adults and children hospitalised with severe presentations of the disease. The company also launched a 24/7 helpline where patients and healthcare practitioners can access information about Remdesivir and its availability.
Priced at Rs 4,800 Mylan released the first batch of its generic Remdesivir (DESREMTM) and will continue to increase its supply across the country as per its demand. It is working with the state authorities and hospitals to cater to the rising demand for the drug.
President, India and Emerging Markets, Rakesh Bamzai said, “In the wake of increasing cases of Covid-19 across India, Mylan remains committed to continue its efforts in the fight against the pandemic.”